Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell Epitopes
Open Access
- 15 May 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (10) , 4717-4728
- https://doi.org/10.1128/jvi.80.10.4717-4728.2006
Abstract
A double-blind randomized phase I trial was conducted in human immunodeficiency virus type 1 (HIV-1)-negative subjects receiving vaccines vectored by plasmid DNA and modified vaccinia virus Ankara (MVA) expressing HIV-1 p24/p17 gag linked to a string of CD8+ T-cell epitopes. The trial had two groups. One group received either two doses of MVA.HIVA (2× MVA.HIVA) (n = 8) or two doses of placebo (2× placebo) (n = 4). The second group received 2× pTHr.HIVA followed by one dose of MVA.HIVA (n = 8) or 3× placebo (n = 4). In the pTHr.HIVA-MVA.HIVA group, HIV-1-specific T-cell responses peaked 1 week after MVA.HIVA vaccination in both ex vivo gamma interferon (IFN-γ) ELISPOT (group mean, 210 spot-forming cells/106 cells) and proliferation (group mean stimulation index, 37), with assays detecting positive responses in four out of eight and five out of eight subjects, respectively. No HIV-1-specific T-cell responses were detected in either assay in the 2× MVA.HIVA group or subjects receiving placebo. Using a highly sensitive and reproducible cultured IFN-γ ELISPOT assay, positive responses mainly mediated by CD4+ T cells were detected in eight out of eight vaccinees in the pTHr.HIVA-MVA.HIVA group and four out of eight vaccinees in the 2× MVA.HIVA group. Importantly, no false-positive responses were detected in the eight subjects receiving placebo. Of the 12 responders, 11 developed responses to previously identified immunodominant CD4+ T-cell epitopes, with 6 volunteers having responses to more than one epitope. Five out of 12 responders also developed CD8+ T-cell responses to the epitope string. Induced T cells produced a variety of anti-viral cytokines, including tumor necrosis factor alpha and macrophage inflammatory protein 1β. These data demonstrate that prime-boost vaccination with recombinant DNA and MVA vectors can induce multifunctional HIV-1-specific T cells in the majority of vaccinees.Keywords
This publication has 79 references indexed in Scilit:
- Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag VaccineJournal of Virology, 2006
- Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrenceInternational Journal of Cancer, 2004
- On Immunity Against Infections and Vaccines: Credo 2004Scandinavian Journal of Immunology, 2004
- Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance ofgagandnefand the Presence of Broadly Recognized PeptidesJournal of Virology, 2004
- Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV VaccinesAIDS Research and Human Retroviruses, 2002
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Virus-specific CD8+ T-cell memory determined by clonal burst sizeNature, 1994
- Cytotoxic T-cell memory without antigenNature, 1994
- Effect of Cytokines on HIV Replication in CD4+ Lymphocytes: Lack of Identity with the CD8+ Cell Antiviral FactorCellular Immunology, 1994